Market Overview

GSK and Theravance Announce Completion of the Phase III Programme for Once-Daily LAMA/LABA (UMEC/VI) in COPD

Share:
Related GSK
Earnings Scheduled For July 26, 2017
These Non-Tech Companies Are Investing In An AI Future
What Financial Modeling Says About Gilead Sciences (GuruFocus)

GlaxoSmithKline plc (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the completion of the phase III programme of an investigational LAMA/LABA involving approximately 6,000 patients with chronic obstructive pulmonary disease.

See full press release

Posted-In: News

 

Related Articles (THRX + GSK)

View Comments and Join the Discussion!